CompletedPhase 2NCT00003868

Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia

Studying Acute myeloid leukemia with 11q23 abnormalities

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fred Hutchinson Cancer Center
Principal Investigator
Eneida Nemecek, MD
Fred Hutchinson Cancer Center
Intervention
cyclophosphamide(drug)
Enrollment
40 enrolled
Eligibility
2-55 years · All sexes
Timeline
19992005

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00003868 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia with 11q23 abnormalities

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia with 11q23 abnormalities

← Back to all trials